Clinical Trials Directory

Trials / Completed

CompletedNCT04441684

Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)

Study of the Seroprevalence of SARS-CoV-2 in Hospital Staff in Strasbourg University Hospital, Strasbourg, France

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
1,466 (actual)
Sponsor
University Hospital, Strasbourg, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

COVID-19 is a new emerging disease caused by infection with the SARS-CoV-2 coronavirus, with no specific therapeutic options. Since the end of February 2020, the Strasbourg University Hospital (HUS) had faced a sudden increase of patients with COVID-19 resulted from a SARS-CoV-2 superspreading event (religious meeting). Infected individuals went to regional hospitals, and this led to a cluster of infected healthcare workers at the Strasbourg University Hospitals from the first week of March. To date, several hundred Strasbourg hospital workers have presented a SARS-CoV-2 infection confirmed by the RT-PCR test from a nasopharyngeal sample. Most of them developed a mild form of COVID-19. It is important to understand how far the infection has spread in the hospital staff, and to which extent the individuals who have been infected develop antibodies against SARS-CoV-2.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTBlood sample for serological testSerology tests: * By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland * ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed.

Timeline

Start date
2020-04-17
Primary completion
2020-05-07
Completion
2021-07-16
First posted
2020-06-22
Last updated
2026-01-20

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04441684. Inclusion in this directory is not an endorsement.